Chemotherapy Market

Growing cancer rates are fueling the market growth

Market CAGR for chemotherapy is driven by the rising number of cancer patients. Cancer incidence has climbed globally, overtaking cardiovascular diseases as the second greatest cause of death. This phenomenon is caused by environmental variables such as cigarette use, altered dietary habits, urbanization, and prolonged post-reproductive lifetime. For instance, the World Health Organisation (WHO) estimates that there will be 29.4 million new instances of cancer worldwide by 2040, up from 18.1 million in 2018. Therefore, it is anticipated that the rising incidence of cancer will increase the demand for oncology cancer medications globally throughout the projection period.

Furthermore, the industry will benefit from the population's growing cancer awareness in the next years.

Cancer treatment is developing more quickly than ever. Emerging from the research and development pipeline are several novel treatments frequently combined with other brand-new or current medications. Numerous pharmaceutical companies are funding these revolutionary medication development projects to treat cancer. For instance, Pfizer purchased Array BioPharma in June 2019, intending to expand its oncology footprint and pipeline, starting with a melanoma combination medication that has been licensed and is currently testing for metastatic colorectal cancer. This is expected to accelerate market expansion and grow consumer desire for biosimilar and biologic products.

Another significant element influencing the growth rate of the market for chemotherapy is the rising cost of healthcare, which contributes to the development of its infrastructure. Government organizations' efforts to upgrade the healthcare infrastructure will further impact the market dynamics by increasing funding. Another significant element influencing the growth rate of the market for chemotherapy is the rising cost of healthcare, which contributes to the development of its infrastructure. Government organizations' efforts to upgrade the healthcare infrastructure will further impact the market dynamics by increasing funding.

Rising chemo awareness and an increase in patients undergoing these treatments are further factors expected to speed up the market's growth rate. Because of aging demographics, the demand for chemotherapeutic medications will also expand. Thus, driving the chemotherapy market revenue.

The Global Global Chemotherapy Market Industry is projected to experience substantial growth over the coming years. The market is expected to reach a value of 9.6 USD Billion in 2024 and is anticipated to grow to 20.9 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 7.31% from 2025 to 2035. Such projections indicate a robust demand for chemotherapy treatments, driven by various factors including advancements in drug development, increasing cancer incidence, and enhanced healthcare access. These figures underscore the market's potential and the critical need for continued investment in cancer therapies.

The Global Global Chemotherapy Market Industry is experiencing growth driven by the increasing incidence of cancer worldwide. According to data from the World Health Organization, cancer cases are projected to rise significantly, with an estimated 19.3 million new cases diagnosed in 2020. This alarming trend necessitates the development and administration of effective chemotherapy treatments, thereby propelling market expansion. As the global population ages and lifestyle factors contribute to higher cancer rates, the demand for chemotherapy is expected to surge, contributing to the market's projected value of 9.6 USD Billion in 2024.

Rising healthcare expenditure globally is a significant factor influencing the Global Global Chemotherapy Market Industry. Governments and private sectors are investing more in healthcare infrastructure and cancer treatment programs. According to the World Bank, global health expenditure has been on an upward trajectory, with many countries allocating larger budgets to oncology services. This increased funding facilitates access to chemotherapy treatments, thereby expanding the market. As healthcare systems evolve and prioritize cancer care, the Global Global Chemotherapy Market is likely to witness sustained growth, with a projected CAGR of 7.31% from 2025 to 2035.

Innovations in chemotherapy drugs are a pivotal driver for the Global Global Chemotherapy Market Industry. The introduction of targeted therapies and immunotherapies has transformed treatment protocols, offering more effective options with fewer side effects. For instance, the development of monoclonal antibodies and small molecule inhibitors has enhanced treatment efficacy for various cancers. These advancements not only improve patient outcomes but also stimulate market growth, as healthcare providers increasingly adopt these novel therapies. The market is anticipated to reach 20.9 USD Billion by 2035, reflecting the impact of these innovations on chemotherapy practices.

Emerging markets are becoming increasingly relevant to the Global Global Chemotherapy Market Industry. Countries in Asia, Africa, and Latin America are witnessing improvements in healthcare access and infrastructure, leading to greater availability of chemotherapy treatments. For instance, initiatives to enhance healthcare systems in India and Brazil have resulted in increased patient access to essential cancer therapies. This trend is likely to contribute to market growth as more patients seek treatment. The Global Global Chemotherapy Market is poised for expansion, with emerging economies playing a crucial role in shaping future demand.

The Global Global Chemotherapy Market Industry benefits from heightened awareness of cancer and the importance of early detection. Public health campaigns and screening programs have been instrumental in educating populations about cancer risks and the necessity for timely treatment. For example, initiatives led by the American Cancer Society have significantly increased screening rates, leading to earlier diagnoses. This proactive approach not only improves survival rates but also drives demand for chemotherapy as a treatment option. As awareness continues to grow, the market is expected to expand, reflecting the critical role of education in cancer management.

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American chemotherapy market area will dominate this market. Multiple manufacturers of chemotherapy drugs and increased healthcare spending are North America's main market drivers. Accessibility to medical facilities and the application of cutting-edge technology in the study and treatment of cancer are other factors driving the market.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2: CHEMOTHERAPY MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe’s chemotherapy market accounts for the second-largest market share. The main drivers influencing the market's growth are the ease of regulatory approval for novel cancer therapies in Europe, the rising incidence of cancer, and significant R&D spending by the major companies in the market. According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.

Further, the German chemotherapy market held the largest market share, and the UK chemotherapy market was the fastest-growing market in the European region

The Asia-Pacific Chemotherapy Market is estimated to expand at a rapid rate from 2024 to 2032. It results from expanded government awareness initiatives and rising healthcare costs in this area. Due to the availability of trained and qualified healthcare providers and the rising need for chemotherapy drugs, the expanding accessibility of generic medications will also help to slow the market's rate of progress in this sector. Moreover, China’s chemotherapy market held the largest market share, and the Indian chemotherapy market was the fastest-growing market in the Asia-Pacific region.

Leading market players are largely investing in R&D to expand their production capacities, which will aid in the further expansion of the chemotherapy industry. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The chemotherapy industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the chemotherapy industry to increase the market sector and benefit customers is local manufacturing to lower operational costs. Recently, the chemotherapy industry has stipulated some of the most important medicinal benefits. Major players in the chemotherapy market, including Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US), and others, are funding operations for research and development to boost market demand.

Gland Pharma, founded in 1978 in Hyderabad, India, has evolved from a contract manufacturer [HK1] of small volume liquid parenteral products to one of the world's largest and fastest growing generic injectables manufacturing companies, with a footprint spanning 60 countries, including the Europe, United States, Canada, Australia, India, and other markets. In May 2022, Gland Pharma, in collaboration with a partner, released Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US market. It is bioequivalent and therapeutically equivalent to Takeda Pharmaceuticals U.S.A., Inc.'s reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial.

AstraZeneca was created in 1999 by merging Astra of Sweden and Zeneca Group of the United Kingdom. The company sells branded medications in various therapeutic areas, including gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. Most sales are done in foreign markets, with the United States making up nearly one-third of the total. In July 2021, AstraZeneca announced that the National Medical Products Administration (NMPA) had approved Imfinzi (durvalumab) for marketing in China for the medical management of patients with Stage III unresectable non-small cell lung cancer whose cancer did not advance following concurrent platinum-based chemotherapy and radiation therapy.